Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
about
Catecholaminergic polymorphic ventricular tachycardia: An exciting new eraGenetics of inherited primary arrhythmia disordersCalmodulin regulation (calmodulation) of voltage-gated calcium channelsSudden unexplained death in infants and children: the role of undiagnosed inherited cardiac conditionsIon Channels in the HeartTowards a Unified Theory of Calmodulin Regulation (Calmodulation) of Voltage-Gated Calcium and Sodium ChannelsChannel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular CardiomyocytesPatient Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Development and Screening In Catecholaminergic Polymorphic Ventricular TachycardiaInherited ion channel diseases: a brief reviewRecent advances in genetic testing and counseling for inherited arrhythmiasCurrent topics in catecholaminergic polymorphic ventricular tachycardiaArrhythmogenic calmodulin mutations impede activation of small-conductance calcium-activated potassium currentSpectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141GNovel CPVT-Associated Calmodulin Mutation in CALM3 (CALM3-A103V) Activates Arrhythmogenic Ca Waves and Sparks.TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVTNew Family With Catecholaminergic Polymorphic Ventricular Tachycardia Linked to the Triadin Gene.Novel calmodulin mutations associated with congenital arrhythmia susceptibility.A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.Calmodulin mutations causing catecholaminergic polymorphic ventricular tachycardia confer opposing functional and biophysical molecular changes.The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.Novel CALM3 mutations in pediatric long QT syndrome patients support a CALM3-specific calmodulinopathy.Impact of genetics on the clinical management of channelopathies.Multiple modes of ryanodine receptor 2 inhibition by flecainide.CALM3 mutation associated with long QT syndromeFunctional role of voltage gated Ca(2+) channels in heart automaticity.Impaired calcium-calmodulin-dependent inactivation of Cav1.2 contributes to loss of sarcoplasmic reticulum calcium release refractoriness in mice lacking calsequestrin 2.Gender Differences in the Inheritance Mode of RYR2 Mutations in Catecholaminergic Polymorphic Ventricular Tachycardia PatientsCommon Variants in TRDN and CALM1 Are Associated with Risk of Sudden Cardiac Death in Chronic Heart Failure Patients in Chinese Han PopulationmTOR signaling in mice with dysfunctional cardiac ryanodine receptor ion channel.Calmodulin 2 Mutation N98S Is Associated with Unexplained Cardiac Arrest in Infants Due to Low Clinical Penetrance Electrical DisordersUric Acid and Cardiovascular Events: A Mendelian Randomization Study.Conserved properties of individual Ca2+-binding sites in calmodulinElucidation of transcriptome-wide microRNA binding sites in human cardiac tissues by Ago2 HITS-CLIPCalmodulin mutations associated with recurrent cardiac arrest in infants.A statistical framework to guide sequencing choices in pedigrees.The Arrhythmogenic Calmodulin p.Phe142Leu Mutation Impairs C-domain Ca2+ Binding but Not Calmodulin-dependent Inhibition of the Cardiac Ryanodine ReceptorDivergent Soybean Calmodulins Respond Similarly to Calcium Transients: Insight into Differential Target Regulation.Recent genetic discoveries implicating ion channels in human cardiovascular diseasesDivergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances
P2860
193bdd3af66a6520d1c36791220ccc46036f375b453166e834eebf19d282f2f5d7234a1da7ecb0985a2e66e2ef071b928c5719438af5d39bf6d78fac907861c76be424e583d83d0b118a9d5658940681ae332ebb804ea17b7f3b03196352cec394a4e1d9bcf5a40f8005dc8ba49b9b9d663e864ba4b82bd8c9c90d08fda1082aac8e5171f7f517b57b97670dd81345d773a7bc75cbc114d436788f80e04e2b41e06c1cba3cee6a15848dea62ab3ff8cb6bea6c31fe956f67a0a1872ef9eac387283a6417ec73392a
P248
Q26747056-022139AB-5BAD-4EC4-A224-8456E005F194Q26783570-D958B5D5-48C8-4C21-B648-EE162AC67026Q26827282-AFC9B11F-AA2A-4705-914D-686B9799E11AQ26827729-0364FBED-CD43-4ACF-990C-852901A47B91Q26829681-4AFA5098-F14D-498C-A7B9-898887FCF44BQ27002550-2B2B17E0-E10F-4A0F-A220-14E0C49EE4B2Q27303698-D41BD5EE-F24F-4FA4-BC2B-85060B85B66FQ28067569-DE78F239-AAF8-4D1B-91CB-C04CD60E8D12Q28071914-F64FFC3F-E1AF-43FC-A879-6BCE82E61662Q28074154-E6420BCF-EFA8-496A-B608-B2CBE7F657D8Q28076784-30FEC2A3-6DB7-4E08-9ED4-B09A581F1418Q29147431-0F535E63-87A0-4736-AB1A-688E966E5742Q29147570-3694811F-19EC-4375-906E-9F71210ED31AQ29347555-9B5A6EEB-7EF2-4AA9-BAB3-9C0BE40C77FAQ29465809-402323DB-CF74-43F8-9E57-20293E804153Q30982059-B9A2C969-6527-41CE-ABD0-8A50BBD6FEE9Q33164413-6AA4EB33-C325-48E2-92BA-F5E071AA87B5Q33164590-4D62A08B-72AE-4658-87E5-70AD21A772BFQ33165145-737CDE62-8D00-4689-AAAE-3A901ACB0540Q33167418-8D7D825C-BB53-4C97-BF46-73D13803AD7EQ33643625-43FDA136-45A9-46B3-BEC6-856848ADC0F8Q34036797-D6A3C369-A9EC-4D6A-A0DD-B5D6A4245A5EQ34441392-FB659253-5EF9-4B83-A131-B947921AEC2EQ34451319-8ACDCFBA-A8EE-4F4D-B54A-A5DA95E2BA28Q35037204-DC772A10-45CD-4EEC-BB09-0E514FCA6F85Q35514666-B2B9920C-7F75-4AB2-B288-C9F7A433192DQ35675536-D2EE7D6C-B000-42EB-8214-71990602F0CBQ35702068-9290280E-7490-409A-B1A2-0F188233FEB0Q35990556-584199CA-5062-440B-B427-4838183417DBQ35995795-77757F43-D8B4-4739-ADD0-72206263F3E6Q36223277-BF539864-5232-4608-99D0-386786D6DA74Q36659085-3C72F957-CBF6-4681-BE75-E725EB9F5A5AQ37228910-F2F55E0A-B8B7-45B3-B28C-E4F8AB01A4FDQ37327429-6358043A-EF9A-4CDE-A0D5-7288BDA7AA1BQ37592304-8A8CC25B-5E55-448F-AD14-2F6E15F0688EQ37610015-4CC2833D-96A2-49A5-A6BF-6548E1E3EEDEQ37642018-C1F726C6-7FC8-4452-9B43-9692B8D0FE72Q37699206-A89798BE-7641-41C8-81F5-57B1F7F04A52Q37708601-6FB93356-474B-4AEB-B06D-4092771D0554Q37728178-22CEC8A7-10B8-4DC8-B52E-EAF09FA0D272
P2860
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@ast
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en-gb
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@nl
type
label
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@ast
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en-gb
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@nl
prefLabel
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@ast
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en-gb
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@nl
P2093
P2860
P50
P921
P3181
P1476
Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death
@en
P2093
A John Camm
Göran Wettrell
Inger Fosdal
Jacob Lund
Lasse L Hildebrandt
Marta Vranas
Michael Christiansen
P2860
P304
P3181
P356
10.1016/J.AJHG.2012.08.015
P407
P50
P577
2012-10-01T00:00:00Z